HeartFlow Inc. has struck a deal with medtech giant, Philips Healthcare, to widen the sales reach of its its HeartFlow FFRct Analysis technology for diagnosing coronary heart disease (CAD). Under the terms of the agreement, the Dutch healthcare group will promote the use of HeartFlow's technology alongside its own coronary fractional flow reserve (FFR), instant wave-free ratio (iFR) and intravascular ultrasound (IVUS) advanced catheters that it gained through its $1.2bn acquisition of Volcano Corp. back in 2015.
HeartFlow FFRct Analysis is the first commercially available non-invasive technology for CAD that gives interventional cardiologists insight into the extent of arterial narrowing and the impact the blockage has on the blood flow. The software system uses deep learning technology to turn cardiac computed tomography (CT) data into 3-D images of the cardiac anatomy, including a map of the coronaries